TP53 and Lynch syndrome: The new classification includes four subgroups: DNA polymerase epsilon (POLE)-mutated tumors; tumors with high microsatellite instability (MSI) or DNA mismatch repair mechanism (dMMR) deficiency, which identifies patients at risk for Lynch syndrome (LS) [12,13]; tumors with p53 alterations (p53-mutants), or high copy-number; and tumors with no specific molecular profile (NSMP), or low copy-number.